Please select the option that best describes you:

Will you be changing your management of locally advanced cervical cancer based on the results of the INTERLACE trial presented at ESMO 2023?   

The trial showed an overall survival benefit of 8% at 5 years with induction chemotherapy (80% vs 72%) utilizing at least 5 cycles of carboplatin-paclitaxel vs standard treatment.



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice
Comments
Radiation Oncologist at Allan Blair Cancer Centre
I do wonder in certain cases if it’s possibl...
Sign in or Register to read more